Citius Cash And Short Term Investments vs Short Term Debt Analysis

CTXR Stock  USD 3.06  0.21  6.42%   
Citius Pharmaceuticals financial indicator trend analysis is way more than just evaluating Citius Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Citius Pharmaceuticals is a good investment. Please check the relationship between Citius Pharmaceuticals Cash And Short Term Investments and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

Cash And Short Term Investments vs Short Term Debt

Cash And Short Term Investments vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Citius Pharmaceuticals Cash And Short Term Investments account and Short Term Debt. At this time, the significance of the direction appears to have no relationship.
The correlation between Citius Pharmaceuticals' Cash And Short Term Investments and Short Term Debt is 0.05. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Citius Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Citius Pharmaceuticals' Cash And Short Term Investments and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Citius Pharmaceuticals are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Cash And Short Term Investments i.e., Citius Pharmaceuticals' Cash And Short Term Investments and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.05
Relationship DirectionPositive 
Relationship StrengthInsignificant

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Citius Pharmaceuticals balance sheet. This account contains Citius Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Citius Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Short Term Debt

Most indicators from Citius Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Citius Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.At this time, Citius Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 12/12/2024, Tax Provision is likely to grow to about 695.5 K, while Enterprise Value Over EBITDA is likely to drop (63.66).

Citius Pharmaceuticals fundamental ratios Correlations

0.410.640.771.0-0.88-0.930.710.870.870.940.940.890.910.960.050.940.98-0.940.980.970.620.510.98-0.050.63
0.410.550.480.39-0.44-0.380.270.450.450.440.320.520.560.420.740.420.4-0.430.390.370.50.50.390.570.49
0.640.550.840.62-0.49-0.640.550.520.520.660.560.640.710.530.490.650.54-0.660.630.620.760.730.680.330.71
0.770.480.840.75-0.49-0.840.890.480.480.80.770.870.90.620.310.80.69-0.820.830.830.780.680.840.160.8
1.00.390.620.75-0.9-0.910.680.880.880.940.930.870.890.970.040.930.98-0.930.970.960.610.50.98-0.060.62
-0.88-0.44-0.49-0.49-0.90.7-0.39-0.99-0.99-0.75-0.71-0.69-0.67-0.97-0.06-0.72-0.860.76-0.79-0.76-0.47-0.43-0.78-0.09-0.45
-0.93-0.38-0.64-0.84-0.910.7-0.84-0.7-0.7-0.91-0.96-0.94-0.95-0.82-0.03-0.92-0.910.99-0.97-0.98-0.67-0.55-0.960.08-0.66
0.710.270.550.890.68-0.39-0.840.380.380.70.760.880.850.550.020.720.66-0.80.80.820.70.580.790.010.73
0.870.450.520.480.88-0.99-0.70.381.00.740.70.680.660.960.050.710.85-0.760.780.750.480.450.770.090.44
0.870.450.520.480.88-0.99-0.70.381.00.740.70.680.660.960.050.710.85-0.760.780.750.480.450.770.090.44
0.940.440.660.80.94-0.75-0.910.70.740.740.960.860.930.870.191.00.96-0.890.950.950.550.420.95-0.020.56
0.940.320.560.770.93-0.71-0.960.760.70.70.960.890.930.850.020.970.96-0.940.980.980.540.390.97-0.180.55
0.890.520.640.870.87-0.69-0.940.880.680.680.860.890.960.790.110.860.86-0.950.930.930.680.570.920.110.7
0.910.560.710.90.89-0.67-0.950.850.660.660.930.930.960.80.20.930.89-0.940.950.950.680.560.950.040.7
0.960.420.530.620.97-0.97-0.820.550.960.960.870.850.790.80.050.860.95-0.850.90.880.510.430.9-0.010.51
0.050.740.490.310.04-0.06-0.030.020.050.050.190.020.110.20.050.170.03-0.040.040.030.360.370.050.650.38
0.940.420.650.80.93-0.72-0.920.720.710.711.00.970.860.930.860.170.95-0.890.950.960.550.410.95-0.050.56
0.980.40.540.690.98-0.86-0.910.660.850.850.960.960.860.890.950.030.95-0.910.970.960.510.390.96-0.130.52
-0.94-0.43-0.66-0.82-0.930.760.99-0.8-0.76-0.76-0.89-0.94-0.95-0.94-0.85-0.04-0.89-0.91-0.97-0.96-0.71-0.6-0.96-0.01-0.69
0.980.390.630.830.97-0.79-0.970.80.780.780.950.980.930.950.90.040.950.97-0.971.00.640.520.99-0.090.66
0.970.370.620.830.96-0.76-0.980.820.750.750.950.980.930.950.880.030.960.96-0.961.00.640.50.99-0.110.65
0.620.50.760.780.61-0.47-0.670.70.480.480.550.540.680.680.510.360.550.51-0.710.640.640.980.670.430.98
0.510.50.730.680.5-0.43-0.550.580.450.450.420.390.570.560.430.370.410.39-0.60.520.50.980.540.510.94
0.980.390.680.840.98-0.78-0.960.790.770.770.950.970.920.950.90.050.950.96-0.960.990.990.670.54-0.070.68
-0.050.570.330.16-0.06-0.090.080.010.090.09-0.02-0.180.110.04-0.010.65-0.05-0.13-0.01-0.09-0.110.430.51-0.070.42
0.630.490.710.80.62-0.45-0.660.730.440.440.560.550.70.70.510.380.560.52-0.690.660.650.980.940.680.42
Click cells to compare fundamentals

Citius Pharmaceuticals Account Relationship Matchups

Citius Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets43.8M142.4M114.0M103.6M119.2M125.1M
Short Long Term Debt Total1.4M855.5K678.2K481.2K553.4K476.4K
Other Current Liab1.7M2.4M3.0M2.6M3.0M1.7M
Total Current Liabilities4.1M4.0M4.5M5.8M6.6M7.0M
Total Stockholder Equity33.7M132.2M102.8M90.8M104.5M109.7M
Net Debt(12.5M)(69.2M)(41.0M)(26.0M)(23.4M)(22.2M)
Retained Earnings(70.6M)(96.0M)(129.7M)(162.2M)(146.0M)(138.7M)
Accounts Payable1.9M1.3M1.2M2.9M3.4M3.5M
Cash13.9M70.1M41.7M26.5M30.5M16.0M
Cash And Short Term Investments13.9M70.1M41.7M26.5M30.5M16.0M
Common Stock Total Equity28.9K55.6K146.0K146.2K168.1K176.6K
Common Stock Shares Outstanding39.2M108.6M146.1M151.3M174.0M182.7M
Liabilities And Stockholders Equity43.8M142.4M114.0M103.6M119.2M125.1M
Non Current Liabilities Total6.0M5.7M6.0M6.4M7.4M7.7M
Total Liab10.1M9.6M10.6M12.2M14.0M14.7M
Total Current Assets14.0M72.8M44.6M34.4M39.5M41.5M
Short Term Debt491.0K354.5K394.0K218.4K251.1K340.8K
Common Stock55.6K146.0K146.2K158.9K182.7K191.8K
Net Tangible Assets(1.6M)33.7M132.2M102.8M118.2M124.2M
Retained Earnings Total Equity(55.8M)(70.6M)(96.0M)(129.7M)(116.7M)(110.9M)
Capital Surpluse80.2M104.2M228.1M232.4M267.2M280.6M
Other Stockholder Equity104.2M228.1M232.4M252.9M290.8M305.4M
Non Current Assets Total29.8M69.6M69.4M69.2M79.6M83.6M
Other Current Assets122.2K2.7M2.9M7.9M9.1M9.5M
Property Plant Equipment590.01.6K7.0K4.1K4.7K3.0K
Property Plant And Equipment Net987.8K829.9K650.2K455.9K524.2K403.2K
Property Plant And Equipment Gross987.8K829.9K650.2K455.9K524.2K403.2K
Net Invested Capital34.0M132.2M102.8M90.8M104.5M68.3M
Net Working Capital9.9M68.8M40.0M28.6M32.9M24.9M
Capital Stock55.6K146.0K146.2K158.9K182.7K101.2K

Pair Trading with Citius Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Citius Stock

  0.77JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.76LLY Eli LillyPairCorr

Moving against Citius Stock

  0.88BMY Bristol Myers SquibbPairCorr
  0.83ESPR Esperion TherapeuticsPairCorr
  0.78CAH Cardinal HealthPairCorr
  0.67XAIR Beyond AirPairCorr
  0.64GILD Gilead SciencesPairCorr
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Citius Stock Analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.